8-K: Revvity Reports Mixed Q4 and Full Year 2023 Results, Issues 2024 Guidance

Revvity's fourth quarter results show a revenue decrease, but the company initiates full year 2024 guidance with projected revenue between $2.79-$2.85 billion and adjusted EPS of $4.55-$4.75.

Summary

• Revvity announced its financial results for the fourth quarter and full year ended December 31, 2023.
• Fourth quarter revenue was $696 million, a decrease of 6% reported and 7% organically, with a 3% decrease in non-COVID organic growth.
• GAAP earnings per share for the fourth quarter were $0.64, down from $1.01 in the same period last year.
• Adjusted earnings per share from continuing operations for the fourth quarter were $1.25, compared to $1.41 in the prior year.
• Full year 2023 revenue was $2.751 billion, a decrease from $3.312 billion in 2022.
• GAAP earnings per share for the full year were $5.55, up from $4.50 in 2022.
• Adjusted earnings per share from continuing operations for the full year were $4.65, down from $6.92 in 2022.
• The company has initiated full year 2024 guidance, forecasting total revenue of $2.79-$2.85 billion and adjusted earnings per share of $4.55-$4.75.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While the company is providing forward guidance and highlighting innovation, the year-over-year declines in revenue and adjusted EPS are concerning.

Positives

• Full year GAAP earnings per share increased to $5.55 from $4.50 in the previous year.
• The company initiated full year 2024 guidance, providing a forward-looking perspective.
• Revvity's management stated they performed better than anticipated during the final months of 2023.
• The company is focusing on innovation to be a strategic scientific partner with its customers.

Negatives

• Fourth quarter revenue decreased by 6% year-over-year.
• Organic revenue decreased by 7% in the fourth quarter.
• Non-COVID organic revenue decreased by 3% in the fourth quarter.
• GAAP EPS for Q4 decreased to $0.64 from $1.01 in the same period last year.
• Adjusted EPS from continuing operations for Q4 decreased to $1.25 from $1.41 year-over-year.
• Full year revenue decreased to $2.751 billion from $3.312 billion in 2022.
• Full year adjusted EPS from continuing operations decreased to $4.65 from $6.92 in 2022.
• The Diagnostics segment experienced a significant 28% decrease in reported revenue for the full year.

Risks

• The company faces risks related to market declines, the impact of the COVID-19 pandemic, and fluctuations in the global economy.
• There are risks associated with introducing new products, executing acquisitions, and competing effectively.
• Disruptions in supply chains, information technology systems, and the loss of key personnel are also potential risks.
• The company's ability to obtain future financing and comply with regulations are also listed as risks.

Future Outlook

The company forecasts total revenue of $2.79-$2.85 billion and adjusted earnings per share of $4.55-$4.75 for the full year 2024.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company persevered through industry headwinds and performed better than anticipated during the final months of 2023.
• Management believes they are leading with innovation to be a strategic scientific partner with their customers.

Industry Context

The results reflect ongoing challenges in the health science industry, with a notable decrease in COVID-related revenues impacting the Diagnostics segment. The company's focus on innovation and strategic partnerships aligns with the broader industry trend of seeking long-term growth through diversified offerings.

Comparison to Industry Standards

• Revvity's performance is mixed when compared to industry peers. Companies like Thermo Fisher Scientific and Danaher have shown more resilience in their diagnostics segments, while life sciences tools and services have seen more consistent growth.
• The decrease in Revvity's diagnostics revenue is more pronounced than some of its competitors, indicating potential challenges in that specific market segment.
• The company's 2024 guidance suggests a focus on stabilizing revenue and improving profitability, which is a common strategy among companies facing similar headwinds.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and adjusted EPS, but the 2024 guidance provides some reassurance.
• Employees may be affected by any restructuring or cost-cutting measures taken to improve profitability.
• Customers may benefit from the company's focus on innovation and strategic partnerships.
• Suppliers and creditors may be impacted by the company's financial performance and future outlook.

Next Steps

• The company will discuss its fourth quarter and full year 2023 results and its outlook for business trends during a webcast on February 1, 2024.
• Revvity will continue to focus on innovation and strategic partnerships to drive future growth.

Key Dates

Keywords

financial results, revenue, earnings per share, EPS, organic growth, guidance, life sciences, diagnostics, non-GAAP, adjusted EPS